author-photo

Harry P. Erba

University of Alabama at Birmingham
University of Michigan
Duke University

337

Papers

9478

Citations

Citation Trend

Filter By

Papers (336) Sort By

Journal Conference Others

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes of patients with IDH1 -mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (3)
Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.

2021 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (0)
Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)